Saturday 17 October 2026
Export EOLS’s income statement to Excel — free account
Evolus, Inc.
EOLS Healthcare Drug Manufacturers Specialty & Generic
Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS grew 55.6%, free cash flow grew 84.9% and total debt rose 7.75%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
7.10
0.47
−6.21%
Follow EOLS
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 6 | 5 | 2 | 4 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z-Score |
(1.87) | (0.75) | (1.81) | (2.34) | (0.81) | (4.72) | (0.53) | — | — | — |
P/S ratio |
1.44 | 2.57 | 2.81 | 2.95 | 3.25 | 2.00 | 0.00 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(8.65) | (7.02) | (9.27) | (9.45) | (2.94) | (12.71) | (1.65) | — | — | — |
Beneish M-Score |
(2.59) | (2.68) | (3.03) | (1.67) | (1.92) | (5.03) | — | — | — | — |
P/Operating CF |
33.42 | 142.40 | 699.41 | (50.03) | (35.83) | (50.03) | (21.58) | — | — | — |
P/B ratio |
0.00 | 123.99 | 0.00 | 23.73 | 3.96 | 0.00 | 4.33 | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 32.26 | 0.00 | 0.00 | — | — | — |
EV/Sales |
2.00 | 2.98 | 3.47 | 3.58 | 3.24 | 2.13 | 0.00 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
(14.09) | (44.09) | (20.60) | (6.26) | (9.69) | (2.09) | (3.09) | — | — | — |
EV/FCF |
(11.74) | (34.77) | (19.66) | (6.05) | (9.41) | (1.98) | (2.95) | — | — | — |
Quick Ratio |
1.44 | 2.14 | 1.93 | 1.64 | 2.79 | 0.65 | 5.75 | 17.66 | 0.34 | 0.00 |
Current Ratio |
1.90 | 2.40 | 2.33 | 2.17 | 3.10 | 0.71 | 6.23 | 17.88 | 0.34 | 0.00 |
Net Debt/EBITDA |
(4.08) | (1.27) | (1.36) | (0.30) | 2.03 | (0.05) | 0.59 | 1.68 | (6.31) | (3.03) |
Debt/Assets |
64.68% | 52.25% | 63.68% | 40.39% | 27.66% | 54.95% | 31.07% | 9.84% | 47.72% | 77.11% |
Debt/Equity |
(6.32) | 22.00 | (5.82) | 3.89 | 0.87 | (1.57) | 0.94 | 0.20 | (0.96) | (8.41) |
Asset Turnover |
1.30 | 1.26 | 1.10 | 0.68 | 0.43 | 0.25 | 0.17 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.82 | 0.36 | 0.55 | 1.14 | 0.71 | 0.36 | 1.04 | 0.55 | 2.95 | 0.66 |
Capex/Depreciation |
(0.84) | (0.67) | (0.23) | (0.53) | (0.13) | (0.32) | (0.75) | (0.01) | 0.00 | 0.00 |
Interest Coverage |
(1.66) | (1.84) | (3.56) | (7.18) | (31.81) | (14.57) | (12.44) | (53.47) | (2,345.20) | — |
| 587.36% | 664.86% | 5,633.33% | (148.27%) | (1,049.79%) | (5,016.56%) | (109.90%) | (1,060.22%) | 10.84% | (819.65%) | |
| (22.53%) | (23.92%) | (33.62%) | (34.18%) | (20.07%) | (72.53%) | (43.68%) | (28.92%) | (3.90%) | (25.27%) | |
ROIC |
(29.51%) | (53.67%) | (83.54%) | (112.00%) | (405.63%) | 0.00% | (253.85%) | (354.89%) | 0.00% | (23.78%) |
Return on Tangible Assets |
(70.76%) | (55.04%) | (93.16%) | (130.76%) | (38.21%) | 317.52% | (69.98%) | (52.62%) | 3.20% | 31.80% |
Average Days of Receivables |
67.18 | 65.36 | 55.14 | 55.13 | 53.67 | 62.49 | 111.42 | — | 0.00 | — |
Research and Development Expense of Revenue |
3.22% | 3.44% | 3.24% | 3.19% | 2.07% | 3.05% | 11.38% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
74.29% | 74.37% | 81.62% | 95.44% | 112.44% | 173.66% | 325.25% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.31 | 0.30 | 0.36 | 0.39 | 0.28 | 0.37 | 0.34 | 0.45 | 0.51 | 1.00 |
Share Based Compensation of Revenue |
6.96% | 8.36% | 8.14% | 7.29% | 9.61% | 18.72% | 27.25% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.25) | (0.11) | (0.17) | (0.13) | 0.01 | (1.36) | (0.03) | — | — | — |
Graham Number |
2.56 | 0.00 | 2.99 | 0.00 | 0.00 | 15.35 | 0.00 | — | — | — |
Earnings Yield |
(12.18%) | (7.34%) | (10.91%) | (16.86%) | (12.60%) | (144.05%) | (26.46%) | — | — | — |
Free Cash Flow Yield |
(11.83%) | (3.33%) | (6.27%) | (20.01%) | (10.60%) | (53.82%) | (28.50%) | — | — | — |
Revenue per Share |
4.61 | 4.29 | 3.55 | 2.65 | 2.00 | 1.68 | 1.24 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.66) | (0.29) | (0.60) | (1.51) | (0.67) | (1.72) | (3.31) | (1.05) | (0.80) | (0.80) |
Capex per Share |
(0.13) | (0.08) | (0.03) | (0.05) | (0.02) | (0.09) | (0.16) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.79) | (0.37) | (0.63) | (1.57) | (0.69) | (1.81) | (3.47) | (1.05) | (0.80) | (0.80) |
Cash per Share |
0.83 | 1.40 | 1.10 | 0.96 | 2.94 | 3.19 | 4.60 | 3.82 | 0.00 | 0.01 |
Shareholders Equity per Share |
(0.36) | 0.09 | (0.36) | 0.33 | 1.65 | (2.16) | 2.81 | 3.46 | (4.57) | (0.43) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.36) | 0.09 | (0.36) | 0.33 | 1.65 | (2.16) | 2.81 | 3.46 | (4.57) | (0.43) |
Free Cash Flow |
(50.72) | (22.82) | (35.63) | (87.85) | (34.36) | (61.01) | (97.95) | (25.68) | (13.22) | (13.27) |
Working Capital |
67.61 | 88.38 | 64.13 | 54.29 | 121.14 | (52.64) | 127.76 | 89.06 | (139.92) | (63.10) |
Capital Expenditures |
(8.45) | (4.82) | (1.63) | (2.94) | (0.97) | (3.14) | (4.57) | (0.01) | — | — |
Net Current Asset Value |
(106.06) | (75.70) | (97.27) | (58.68) | 3.19 | (154.41) | (8.79) | 6.88 | (154.95) | (84.39) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.03 | 0.02 | 0.01 | 0.02 | 0.01 | 0.06 | 0.13 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.87 | 2.22 | 3.35 | 2.13 | 5.49 | 7.67 | 6.79 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
(28.68%) | (10.67%) | (21.93%) | (60.88%) | (11.48%) | (40.81%) | (34.49%) | (13.20%) | 455.30% | (25.11%) |
Accounts Receivable Turnover |
5.81 | 6.81 | 7.63 | 8.01 | 8.19 | 5.56 | 0.84 | — | 0.00 | — |
Accounts Payable Turnover |
6.14 | 12.43 | 9.77 | 7.83 | 5.54 | 2.37 | 2.18 | 0.01 | 0.13 | 0.21 |
Inventory Turnover |
5.12 | 7.25 | 4.32 | 5.71 | 17.02 | 3.75 | 1.64 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
85.21 | 40.15 | 24.16 | 55.42 | 51.07 | 191.79 | 263.98 | 63,185.56 | 745.07 | 3,221.18 |
Days of Inventory on Hand |
98.35 | 52.85 | 62.22 | 116.94 | 14.77 | 66.90 | 291.81 | 0.00 | 0.00 | 0.00 |
Average Receivables |
51.19 | 39.11 | 26.49 | 18.55 | 12.17 | 10.17 | 41.65 | — | 41.65 | — |
Average Payables |
16.30 | 6.75 | 6.60 | 7.51 | 7.85 | 7.71 | 3.68 | 1.00 | 1.66 | 1.55 |
Average Inventory |
19.56 | 11.58 | 14.93 | 10.31 | 2.56 | 4.88 | 4.88 | — | — | — |
Average Assets |
229.22 | 210.78 | 183.49 | 217.73 | 233.28 | 224.76 | 206.14 | 162.04 | 114.86 | 79.40 |
Average Common Equity |
(8.79) | (7.58) | (1.09) | 50.19 | 4.46 | 3.25 | 81.92 | 4.42 | (41.32) | 2.45 |
Columns are period end dates